ALLOAllogene Therapeutics, Inc.
This year, Allogene Therapeutics has to prove it can deliver on its promise — and the next big test is the Q3 2026 earnings release on November 11, where the stock is expected to anchor around $1.69, with a bull target of $2.24 and a bear fallback of $1.45. The company’s path forward is a sequence of high-stakes events, each one a test of its ability to execute, raise capital, and deliver results. The modeled bull and bear paths are both steep, and the lean is toward the bear — a sign that the market is skeptical, but not entirely written off.
The Read
Allogene’s stock surged about 51% after confirming a stable cash runway through mid-2027 and meeting EPS estimates, but then dropped about 17% when it raised expense guidance and lost a key Asian cell therapy partner despite positive clinical data.
The schedule
No upcoming catalysts on the current packet.
Past
- Wed12Aug
Actual outcome: Bull · $1.98 at outcome
Allogene Therapeutics (ALLO) beat earnings estimates with an EPS of -0.13 versus the estimate of -0.13. The company also narrowed its Q2 loss due to lower R&D costs and reported a stronger cash position, extending its runway into 2029. Additionally, the company highlighted progress in its clinical pipeline, including expanded enrollment for the ALPHA3 lymphoma study and recent FDA designations for cema-cel, which contributed to the positive stock movement.
Q2 2026 earnings focusing on clinical progress and cash runway update.
- Wed13May
Actual outcome: Bear · $1.94 at outcome
Despite posting a narrower-than-expected Q1 loss and sharing positive interim data from its ALPHA3 study, Allogene's stock fell 16.7% following its business update. The sell-off was driven by the company raising its 2026 expense outlook and the unexpected termination of a key cell therapy partnership in Asia with Overland Therapeutics, which overshadowed the clinical progress.
- Thu12Mar
Actual outcome: Bull · $2.44 at outcome
Allogene met EPS estimates and confirmed its cash runway into the second half of 2027, successfully avoiding the surprise dilutive financing that investors feared. Although the stock experienced a short-term 9.1% pullback following the report, the fundamental confirmation of a stable burn rate and sufficient liquidity to reach major clinical catalysts kept the price well above the $1.75 bull target.
